Xeris Biopharma Holdings, Inc.(XERS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Xeris Biopharma Holdings, Inc. (XERS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XERS at 56.5/100 on a 32-signal composite quality model, placing it at rank #1,160 of 2,960 stocks — the top half of the AI-ranked universe. XERS scores in the top quartile across earnings quality (91.5), revenue growth (90.9). Areas of concern include balance sheet strength (23.6) and revenue scale (31.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xeris Biopharma Holdings, Inc. reports quarterly revenue of $92.1M, net income of $-31.1M. Top institutional holders of XERS by reported 13-F value include BlackRock, CAPSTONE INVESTMENT ADVISORS, D. E. Shaw, based on the most recent SEC filings. XERS trades on the Nasdaq exchange and files with the SEC under CIK 1867096. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XERS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xeris Biopharma Holdings, Inc. directly from SEC EDGAR.